Chief Editors and Future Plans of Oncotarget

Since its inception in 2010, Onoctarget has had several goals which are to provide their large reader base with accurate information and data, help spread the knowledge of latest medical and biological research, as well as to have their issues submitted to PubMed as soon as they go live online.

Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/

The biomedical journal has been working towards accomplishing that goal, and after their 35th and 36th issues have been processed by the National Library of Medicine, they will be added to PubMed. That is a milestone for Oncotarget. Another milestone for the online journal is its d publication schedule. Oncotarget has been publishing once every week e its started in 2010. At the start of 2018, the Oncotarget journal started putting out issues two times a week in order o provide more information about current medical and biological research to its readers. So far, Oncotarget has accomplished seven volumes and s working on its eight one. There is a total of 324 issues as of December 2017. Check the journal at SCImago Journal & Country Rank.

Oncotarget can be accessed by the general public and not only medical experts and practitioners. in order to provide reader base with as accurate an information as possible, Oncotarget is also peer-reviewed. The journal has a hugely extensive editorial board. As it published research in several areas of research, Oncotarget has an advisory board for each discipline such as Immunology, Pathology, Chromosomes, Aging, Autophagy, and more.

Oncotarget has two doctors working as Editor in Chief. Dr. Andrei V. Gudjkov has been working at the Roswell Park Cancer Institute (RPCI) for more than a decade. He is also a Professor and Garman Family Chair in Cell Stress Biology as well as a Senior Vice President for Basic Research at the RPCI. Andrei V. Gudkov, Ph. D. as achieved a degree in molecular biology and experimental oncology. Gudkov co-founded the Cleveland Biolabs, Inc as well as Taris Inc.

Dr, Mikhail Blagosklonny used to work t RPCI as well up until 2016. He graduated from the Russian First Pavlov State University in cardiology and oncology. Dr, Mikhail Blagosklonny has made a substantial contribution through his articles and papers. He is Associate Editors of journals such as Cell Cycle, Cell Death Differ, Cancer Res, and more. Learn more about Oncotarget at Eurekalert.org.